From seed to process-ready raw material
We are establishing a number of grow sites around the world to supply our own production and development of medical preparations. This is where we produce and refine several different medically useful strains of Cannabis Sativa L +0.2% THC. From this raw material we then produce drugs under our own brand, but we also sell white labels on markets where we are not represented.
In 2021 we will have sufficient production capacity primarily to supply raw material to our laboratories, industry colleagues and the pharma sector worldwide. The raw material will comprise both dried plant matter, extracted liquid and kief, all of high purity.
We can see demand for safe, reasonably priced quality raw material increasing as medical cannabis expands onto more and more markets.
There are many different strains on the market, with different properties, strengths and characters. We are focusing on the varieties best suited to medical extracts, which meet end customers’ needs for relaxation or pain relief. With refinement we can also develop more efficient, sustainable and vigorous plants.
»It’s my job to manage the plantations to ensure we get a consistent, high-quality crop every time. We have experienced growers to help us, and I have also been on field trips to colleagues in the US and Canada. We use sophisticated technical solutions to maximize production and focus on sustainability.«
– Andreas Mikulic, Cultivation Manager, Aureum Agricol AB
One important aim is to build up an extensive gene pool, in seed banks and mother plants, to ensure we always have the best possible propagation material.
We are building up our number of sites and are monitoring the market environment as we move into the future. This information may therefore change over time.
In spring 2020 we are starting our first plantation for pharmaceutical production. Estimated volumes:
Year 1: 9,000 kg flowers + 45,000 kg other plant matter.
Year 2: 22,000 kg flowers + 110,000 kg other plant matter.
Year 3: 58,000 kg flowers + 290,000 kg other plant matter.
Zimbabwe and Swaziland
In autumn 2020 we start growing in Africa, focusing on research and development into around 20 different strains. We are planning approximately 5,000 plants in Zimbabwe and as many in Swaziland.
Spring 2021 sees the opening of our combined production and research centre in South America. Our laboratories will house some 24,000 plants, and production will be around 12,000 kg flowers and 60,000 kg of other matter per year.
Denmark, Netherlands and Portugal
We are currently looking into the possibility of opening research and/or production plants in several countries. We are assessing the geographic location, size, volume and business potential.